Pharma and biotech spend tens of billions each year on in‑vitro work, where variability and low first‑try success increse cost and timelines. BinomLabs applies state‑of‑the‑art ML to deliver experiment prognoses that visually align with lab data up to R = 0.93, demonstrated on real in‑vitro studies. With this guidance, teams typically reduce ~10 experiments to 3–4, lifting the proportion of successful first attempts and freeing capital for the highest‑value questions. We enhance expert judgment—turning every scientist into
a faster, more precise decision‑maker.